Head-To-Head Analysis: Cyclacel Pharmaceuticals (CYCC) & Menlo Therapeutics (MNLO)
Cyclacel Pharmaceuticals (NASDAQ: MNLO) and Menlo Therapeutics (NASDAQ:MNLO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
This table compares Cyclacel Pharmaceuticals and Menlo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
5.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 62.1% of Menlo Therapeutics shares are held by institutional investors. 1.5% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Cyclacel Pharmaceuticals and Menlo Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cyclacel Pharmaceuticals||$840,000.00||21.86||-$7.47 million||N/A||N/A|
|Menlo Therapeutics||$4.58 million||38.89||-$29.07 million||($5.69)||-1.36|
Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Menlo Therapeutics.
This is a summary of current ratings and recommmendations for Cyclacel Pharmaceuticals and Menlo Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cyclacel Pharmaceuticals presently has a consensus target price of $7.08, indicating a potential upside of 362.96%. Menlo Therapeutics has a consensus target price of $33.00, indicating a potential upside of 325.81%. Given Cyclacel Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Menlo Therapeutics.
Menlo Therapeutics beats Cyclacel Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
About Menlo Therapeutics
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.